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Spastic Paraplegia with juvenile onset optic Neuropathy 
Case Report 
 
Abstract 
Hereditary Spastic Paraparesis (HSP) represents a group of genetically determined 
heterogeneous diseases. Mutations in the SPG7 (Paraplegin) gene, are responsible for a wide 
range of clinical presentations, varying from an autosomal recessive form of HSP to a form of 
ADON (Autossomal Dominant Optic Neuropathy), whose clinical characteristics are 
physiologically based on mitochondrial dysfunction. The impact of optic involvement 
clinically determined or revealed by supplementary diagnostic means as a clinical biomarker 
of HSP7 is to be valued. 
We present a case report of a 23 year-old, caucasian male with a childhood-onset 
progressive spastic paraplegia with juvenile-onset rapidly progressive severe optic 
neuropathy. We aim to highlight the importance of a complete ophthalmological evaluation 
when a facing a probable neurodegenerative disorder consistent with HSP, in order to 
correctly characterize the underlying clinical syndrome and efficiently request supplementary 
diagnostic exams.   
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Abbreviations 
ADON = Autosomal Dominant Optic Neuropathy; 
BCVA = Best Corrected Visual Acuity;  
CK = Creatine Kinase; EMG = Electromyography;  
DOA = Dominant Optic Atrophy;  
DTI = Diffusion Tensor Imaging; 
FDT = Frequency Doubling Technology perimetry 
HSP = Hereditary Spastic Paraparesis;  
LHON = Leber’s Hereditary Optic Neuropathy; 
RNFL = Retinal Nerve Fiber Layer;  
SDH = Succinate Dehydrogenase;  
SPG7= Spastic Paraplegia Gene 7;  
VEP = Visual Evoked Potentials; ERG =Electroretinography;  
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Introduction 
 
Neurons are important building blocks of the central and peripheral nervous system. 
Neurons are composed of a cell body, the axons (transmit information) and the dendrites 
(receive and process information). The axons represent up to 99% of the total cellular volume, 
and that characteristic emerges as the main cause of their energy dependence to obtain 
proteins and lipids and to eliminate residues.(Rugarli and Langer 2006) 
Genetically affected axons degenerate from the processes towards the cell body, in a 
so called “dying-back” manner, of which HSP is an example.(Rugarli and Langer 2006) 
The pathophysiological process through which axons of cortical motor neurons 
degenerate, ultimately explains the progressive spasticity and weakness in the lower limbs, 
which appear as major characteristics of hereditary spastic paraplegia, an heterogeneous 
genetically determined group of diseases. (Klebe et al. 2012) The estimated prevalence is of 
3-10 per 100,000 in Europe.(Yu-Wai-Man, Griffiths, and Chinnery 2011) 
The type of inheritance of HSP may be autosomal dominant or recessive and X-
linked-recessive. In 80% of the cases, a form of dominant inheritance is present. 
The onset of the HSP often takes place between the age of 10 and 45 years old, 
according to the causative genetic defect, and the observed phenotype expressed may be 
classified as pure or complex taking into account the clinical characteristics of the 
disease.(Klebe et al. 2012; Yu-Wai-Man et al. 2011) 
The pure phenotype is defined by the presence of progressive paraparesis and possible 
posterior column or bladder involvement, in the absence of other additional features.(Arnoldi 
et al. 2008; Klebe et al. 2012; Wilkinson et al. 2004) 
The complex phenotype expresses, in addition to the basic symptoms that define the 
pure phenotype, other neurological signs or clinical features such as cognitive impairment, 
polyneuropathy, generalized epilepsy, hearing impairment, atrophy of corpus callosum, 
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extrapyramidal symptoms and/or tetraspasticity. (Arnoldi et al. 2008; Klebe et al. 2012; 
Wilkinson et al. 2004) 
Mitochondrial Diseases which present with Optic Neuropathy – Pathophysiology 
The HSP causative genes can, according to their hypothetical function, be divided into 
three groups. The axonal trafficking genes (SPG3, SPG4 and SPG10), the myelination and 
neuronal recognition genes (SPG1 and SPG2) and the genes with mitochondrial 
functions.(Rugarli and Langer 2006)  
Three examples of mitochondrial forms of HSP are associated with mutations in the SPG31 
gene (REEP1), the SPG13 gene (heat shock protein) and in the SPG7 gene (Paraplegin). 
The impact of the underlying mutations in the optimal mitochondrial performance, 
which ultimately affects several energy-dependent circuits and exposes cells to oxidative 
stress, results in the clinically identifiable syndromes (Atorino L, et al., 2003).  
There is a tendency for Mitochondrial Diseases to impact retinal function, potentially 
leading to optic neuropathy. This fact can be explained by the high energy-dependence of the 
retinal ganglion cells (RGC). The RGC represent the final output of the retina and their axons 
project inwards to form the optic nerve that subsequently conducts the impulse to the lateral 
geniculate body and subsequently to the occipital lobes of the brain. Posterior to the lamina 
cribosa, the optic nerve is myelinated but in the intraocular portion, the axons remain 
unmyelinated and, therefore, more energy-dependent, in order to transmit the potential of 
action. This is corroborated by the number of mitochondria which is a lot higher in the 
unmyelinated portion, underlining the greater vulnerability to mitochondria dysfunction and 
energy decreased production of that part of the optic pathway.(Carelli et al. 2009) 
Mitochondrial disorders that present with optic neuropathy can be classified as 
syndromic or non-syndromic.(Carelli et al. 2009) In the group of syndromic mitochondrial 
diseases with optic neuropathy, a type of multi-systemic mitochondrial disorder is 
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LHON/dystonia/MELAS/Leigh overlapping syndrome, which results from a defect in 
mtDNA, leading to mitochondrial vasculopathy and affecting the complex I of the 
mitochondria. Genetic errors in nuclear genes that code for mitochondrial proteins, as those 
underlying conditions such as Friedreich Ataxia, Charcot-Marie-Tooth type 2A2, Mohr-
Tranebjerg syndrome (deafness-dystonia-optic atrophy), DOA “plus” syndrome, DOA with 
cataract, Costeff Syndrome and HSP 7, represent different genetic sources for several 
syndromic mitochondrial diseases with optic neuropathy.(Carelli et al. 2009) The non-
syndromic or mono-symptomatic group of mitochondrial diseases causing optic neuropathy 
includes Leber Hereditary Optic Neuropathy (LHON), Dominant Optic Atrophy (DOA: 
OPA1; OPA7; OPA4; OPA5 genes) and also ADON associated with SPG7 gene.(Carelli et al. 
2009) 
Hereditary Spastic Paraplegia Type 7 
Hereditary Spastic Paraplegia type 7 is a form of HSP that results from a mutation in 
the SPG7, encoding Paraplegin that constitutes a subunit of the ubiquitous and ATP-
dependent mAAA protease, which integrates the inner mitochondrial membrane. (Klebe et al. 
2012; Mancuso et al. 2012; Rugarli and Langer 2006)  
SPG7 was the first gene identified as causative of autosomal spastic paraplegia 
(16q24.3) and is composed of 17 exons, with high frequency of rare nucleotide variants of 
unknown status, which makes the interpretation of molecular testing results a complex task. 
Mutations in the SPG7 gene were first identified in 3 families, two with isolated spasticity and 
one with complex phenotype. 
Clinical characteristics and typical evolution of SPG7-related phenotypes remain 
uncertain. Studies have shown that age of onset is higher when compared to the general 
interval of the HSP group (10-45years old), ranging from 18 to 52 years old (median of 39 
y.o.) and patients tend to present a more slowly progressive disease. 
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The HSP7 presents a recessive pattern of inheritance, as a result of a homozygous or 
compound heterozygous genotype. (Klebe et al. 2012) 
The underlying clinical manifestations vary from a pure to a complex phenotype, and 
the features associated with the complex form of disease, in descendent order of frequency, 
are: cerebellar involvement and/or mild cerebellar atrophy, optic neuropathy, ptosis and 
supranuclear palsy.(Klebe et al. 2012) 
Patients might clinically present a pure phenotype but if cerebellar signs/ atrophy are 
identifiable in MRI imaging or if optic neuropathy is diagnosed by OCT (optical coherence 
tomography), a complex subclinical phenotype is present.(Klebe et al. 2012) 
The cerebellar phenotype may be influenced by other genes rather than being a pure 
consequence of Paraplegin defects. Paraplegin associates with AFG3L2 (ATPase 
family gene 3-like 2) to form an Oligomeric mAAA protease complex, that integrates the 
inner membrane of the mitochondria and is functionally active in the Complex I of the 
respiratory chain. Mutations in the AFG3L2 gene are involved in autosomal dominant 
Spinocerebellar Ataxia Type 28, which can present with a homozygous or heterozygous 
genotype. In the homozygous form, the disease mainly presents with pyramidal signs, ptosis 
and/or ophthalmoplegia whereas in the heterozygous state, oculomotor apraxia, dystonia 
and/or progressive myoclonic epiplepsy can be found. (Klebe et al. 2012) 
Variants of the AFG3L2 gene might also act as genetic modifiers of the cerebellar 
profile of patients who test positive for SPG7 mutations. Mutations have been reported in 
exons 10, 15 and 16 but consistent results are yet to be established. 
The mAAA (ATPases Associated with diverse cellular Activities) proteases, namely 
Paraplegin (composed by an association of metallo-peptidase 41 and an ATPase domain), 
have been reported to interfere with the processing of OPA 1 (a conserved dynamin-like 
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GTPase in the inner membrane that regulates the dynamic functioning of the mitochondria) 
through its proteolytic cleavage.(Arnoldi et al. 2008) 
 The OPA1 gene is involved in the pathogenesis of the ADOA (Autosomal Dominant 
Optic Atrophy), which represents an important type of non-syndromic mitochondrial disease 
causing optic neuropathy. After its cleavage by mitochondrial proteases, OPA1 is imported 
into the intermembrane space generating long (L) and short (S) forms of the protein. These 
two forms separately are virtually non-functional, but when bound they trigger mitochondrial 
network fusion. The lack of correct proteolytic cleavage eventually results in mitochondrial 
dysfunction, apoptosis and loss of retinal ganglion cells (RGC).(Arnoldi et al. 2008)   
The protein activation and degradation in mitochondria, by m-AAA proteases are two 
interdependent and mutually influenced processes.  
A role of Paraplegin in the quality control of mitochondria, including maturation of 
proteins involved in ribosome assembly and translation within the mitochondria such as 
MrpL32 (a nuclear-encoded subunit of mitochondrial ribosomes), as well as protein synthesis, 
has been suggested. This can widen the impact of the mutation in SPG7 in the pathogenesis of 
the ADON secondary to SPG7 and HSP7.(Rugarli and Langer 2006) 
Mutations in the SPG7 gene have been studied in yeast and mice, and interesting 
findings have shed some understanding about the subject. Axonal swelling was present in 
mice and probably originated from axonal deficient transport, with subsequent accumulation 
of neurofilaments. These facts link SPG7 HSP to other forms of disease. (Ferreirinha 2004). 
Enlarged abnormal mitochondria were also found in the synaptic terminal of the motor 
neurons’ axons of Paraplegin-deficient mice, fact that was not yet explained. These 
mitochondrial changes were specific of long axons (Ferreirinha 2004). Some putative theories 
have been proposed to explain the abnormal findings in neurons as well as the caudal-cranial 
onset of neurodegenerative symptoms. 
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It has been shown that mitochondria with higher membrane potential are preferably 
located in synapses, whereas old mitochondria tend to be transported towards the cell body in 
order to be replaced. Kinesins and dyneins (motor proteins that move along the microtubules 
inside the cell) have been involved in this selective transport of mitochondria and have also 
been implicated in neurodegeneration. (Miller, K.E. and Sheetz 2004; Reid 2002) Thus, the 
energy deficiency in SPG7 mutants can enlighten the fact that the symptoms derive from 
affected long axons in their distal portion, because mitochondria that are more apart from the 
cell body are more poorly replaced. Another hypothesis is based on clogging of axons by 
enlarged mitochondria that consequently impairs the axonal transport and leads to neuronal 
degeneration.(Chen, H., and Chan 2005; Ferreirinha 2004) 
 
Autosomal Dominant Optic Neuropathy SPG7 
The isolated affection of the optic nerve caused by mutation in the SPG7 gene is an 
uncommon form of Autosomal Dominant Optic Neuropathy (ADON). A heterozygous 
missense, the Asp411Ala mutation, has specifically been linked to this form of ADON. The 
SPG7 gene maps to chromosome 16q24.3, has two alanines downstream of the Walker B 
motif and is up to date, the only naturally occurring missense mutation in the AAA domain of 
the protein. The Walker B motif associates with the Walker A motif to promote the fixation 
and hydrolysis of ATP. Therefore the Asp411Ala mutation alters the binding/hydrolysis of 
ATP, leading to a decrease in proteolytic activity of mAAA proteases in RGC, and to their 
subsequent apoptosis. 
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Diagnostic Criteria 
The diagnosis of SPG7 – HSP is based in the following clinical and contextual 
features: slowly progressive bilateral inferior limbs’ weakness, decreased vibratory sense, 
spasticity, neurological examination showing the presence of a pure (extensor plantar 
responses, hyperreflexia and decrease in lower limbs vibratory sense) or a complex phenotype 
(optic disc pallor, ptosis, dysphagia, cognitive impairment, motor upper limb symptoms, 
bladder involvement, ataxia, nystagmus, strabismus, hearing impairment, scoliosis, pes cavus, 
motor and sensory neuropathy and  muscular atrophy) and the presence of a family history 
supporting an autosomal recessive inheritance.  
Facing a set of symptoms consistent with HSP7, a supplementary evaluation should be 
proposed and there are some expectable findings if the diagnosis is in fact correct. Brain MRI 
may disclose cerebellar/cortical atrophy (Salinas S et al. 2008; Warnecke T et al 2007; 
Wilkinson et al. 2004) and DTI (Diffusion Tensor Imaging – an MRI technique that measures 
the diffusion of water in tissues) white matter abnormalities can be expected, especially if 
located to the frontal lobe, the corticospinal tracks or the brain stem.(Warnecke T et al 2010) 
Functional neurological studies, including spinal evoked potentials or transcranial magnetic 
stimulation, may demonstrate delayed prolongation of central motor conduction time and 
motor threshold in the lower limbs of affected individuals.(Casari G. Marconi R., 2006; 
Warnecke T et al, 2007)  
Muscle biopsies are often performed in patients suspected to carry SPG7 mutations. 
The absence of abnormalities in the muscles biopsy cannot exclude the presence of SPG7 
mutations, as it can simply reflect the early stage of the disease. These biopsies may show 
signs of denervation with partial reinnervation, marked excess of type I fibers probably due to 
the chronic spasticity, atrophic type II fibers and ragged-red fibers (when stained with the 
modified Gomori trichrome) with intense staining with the histochemical reaction to SDH, 
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reflecting the mitochondrial proliferation in an attempt to compensate the OXPHOS defect, 
and negative to cytochrome C oxidase, complex IV of the respiratory chain, which is a 
common denominator among mitochondrial diseases.(Casari et al. 1998) Serum CK may be 
raised and EMG may reveal axonal motor sensory neuropathy. 
Genetic testing provides a definitive diagnosis, as it allows the identification of a 
disease-causing mutation. Sequence analysis may be applied as a first approach. If only one or 
no mutation is found, a deletion/duplication analysis should follow.´ 
Patient and Methods 
We present a case report of a 23 years old caucasian male, exhibiting clinical features 
consistent with hereditary spastic paraplegia, peripheral neuropathy and bilateral rapidly 
progressive optic neuropathy. Detailed phenotypic characterization was performed, including 
family history, best-corrected visual acuity (BCVA), slit-lamp examination, fundus 
examination, fundus photography, FDT perimetry, and electrophysiological studies, in 
accordance with ISCEV guidelines. 
Colour fundus photographies (35º) of both eyes (centered to the macula and to the 
optic nerve) were taken in order to document the features of these structures, with a Topcon 
TRC-50 IA Retinal Ophthalmic Camera. 
Achromatic contrast sensitivity within the magnocellular pathway was probed using a 
perimetric test based on frequency doubling technology Vertically oriented sinusoidal grating 
stimuli were presented monocularly, with a spatial frequency of 0.25 cpd modulated at 25 Hz, 
at different contrast levels, by means of Humphrey Matrix Visual Field Instrument (Carl Zeiss 
Meditec Inc., USA). Analysis was performed considering both global parameters (MD – 
mean defect and PSD – pattern standard deviation) and contrast sensitivity pooled from five 
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regions: the 5º central area (C) and the four visual field quadrants (ST- superior temporal, SN- 
superior nasal, IN- inferior nasal and IT- inferior temporal).  
Conventional Visual Evoked Potentials (Pattern VEPs) were used to measure the 
functional integrity of retino-cortical visual pathways. A RETIport32 (Roland Consult, 
Germany) device was used for stimulation and electrophysiological recordings, with a pattern 
reversal checkerboard stimulus, at a contrast level of 97 %, on a 20 inch monitor at a viewing 
distance of one metre. Two spatial frequencies (60’ and 15’) were monocularly presented at 
1.5 reversals/sec, at a frame rate of 60 Hz.   
Genomic DNA was prepared from venous leukocytes and for genetic testing, coding 
exons and flanking intronic regions of SPG7 and the SPG31 genes were PCR-amplified, 
purified, and sequenced. The SPG7/SPG31 genes were automatically sequenced using 
previously described primer sets.(Elleuch et al. 2006) This was part of an international 
collaboration with Hopital Necker des Enfants Malades, Paris. 
This study was approved by the local ethics committee and followed the tenets of the 
Declaration of Helsinki. Informed consent was obtained from the patient prior to collection of 
clinical data and genomic samples.  
He is integrated in APCC, an association that supports families and patients with 
cerebral palsy, which was the first suspected diagnostic (diplegic form), as the patient also 
presents some degree of cognitive impairment in addition to the early onset of motor 
dysfunction of the lower limbs. Left kidney agenesis was detected in post-natal period. 
Consanguinity was excluded and there was no family history of spastic paraplegia. 
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In 2003, at age 13, the patient underwent his first ophthalmological observation, which 
was within normal limits. 
In 2006, a bilateral loss of visual acuity was determined (BCVA OD 6/10 and OS 
6/10) along with a reduction in pupillary reflexes, no relative afferent papillary defect and 
optic disc pallor OU. The remainder exam was normal. 
Electrophysiological studies were conducted, including pattern and flash VEP and 
ERG. Pattern Visually Evoked Potentials (VEP) appeared bilaterally abolished (Figure 1). 
Flash VEP presented reduced responses at 1,3Hz and 7Hz. (Figure 2) 
Figure 1 – Bilaterally abolished pattern VEPs  
Figure2- Flash VEP displaying very reduced responses at 1,3Hz and 7Hz. 
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Figure 3 – ERG confirming preserved responses in scotopic and photopic conditions.  
ERG revealed normal scotopic and phototopic responses that point towards the 
integrity of the neurosensory retina. Flicker response and oscillatory potentials were also 
within expected intervals (Figure 3) Taken together, the electrophysiological study results are 
suggestive of a optic neuropathy. 
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FDT perimetry demonstrated arcuate scotomas and reduced sensitivity temporal to the 
disc compatible with bilateral temporal optic atrophy with significant drop out of the retinal 
nerve fiber layer (RNFL), with loss of central vision more severe in the left eye (Figure 4).  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – N-30-F FDT Threshold results obtained using standard technique. 
Right Eye 
Left Eye 
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In 2008, BCVA was of 5/10 OD and 2/10 OS. The patient showed no evidence of 
ptosis, ophthalmoplegia and/or strabismus.  
In 2010, at age 20, patient already presented a drop in BCVA to 2/10 OU and at his 
last observation, in October 2013, BCVA was inferior to 1/10 bilaterally, with further drop-
out of the RNFL. 
Molecular testing of the SPG31 and SPG7 genes are underway. Automated sequencing 
of the SPG7 gene was normal in all but three exons. Molecular results are pending. 
 
Discussion 
In contrast with the finding in virtually all studies that age of onset for SPG7-HSP was 
higher (median 39years) and disease course was longer and slowly progressive, our patient 
presents with a juvenile onset, rapidly progressive hereditary spastic paraplegia. (Klebe et al., 
2012; McDermott CJ et al., 2001).  
The main characteristic supporting the hypothesis of a SPG7-HSP in our patient is the 
major optic involvement when associated with symptoms of spasticity and motor impairment 
of lower limbs. 
When analyzing the ophthalmological data, it should be underscored the significant 
vision loss throughout a 10-year period. In 2003 the ophthalmological exam was normal and 
in 2013, the BCVA was below 1/10 in both eyes, which dramatically demonstrates the 
severity of the loss of retinal ganglion cells in this patient.  
Electrophysiological results are highly suggestive of optic neuropathy, with 
preservation of the neurosensory retina as corroborated by the ERG results that showed 
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scotopic (rods), phototopic (cones), flicker (cones) and oscillatory potentials (ischemia) 
normal responses. In addition, pattern and flash VEP (evaluates function of visual pathways 
and striate cortex) showed optic nerve dysfunction, with abolished responses in the tests. 
The temporal half of neuroretinal rim is whiter and reflects the loss of axons of RGC, 
which are replaced by glial tissue. The optic disc pallor is a valuable clinical finding of optic 
neuropathy along with diminished pupillary reflexes that also mirrors visual pathway 
integrity. Both features were present in our patient. 
The optic neuropathy was found in all patients who tested positive for SPG7 mutations 
in a previous large study. (Klebe et al. 2012) This highlights the outstanding importance of an 
ophthalmological observation, when a probable diagnosis of a neurodegenerative disorder 
with lower limb motor impairment and spasticity is suggested. The ophthalmological 
evaluation may precede the genetic analysis in order to provide better guidance to the patient, 
because if an optic neuropathy is diagnosed, the presence of a SPG7 mutation becomes a 
more appealing possibility as the probable cause of the underlying pathology, and genetic 
confirmation is required. After the description of a SPG7 mutation, it is also mandatory to 
follow-up the patient from an ophthalmological standpoint determine the disease impact and 
to infer which treatment should be implemented. 
Our patient is taking a daily dose of coenzyme Q10 therapy (ubiquinone – helps 
transfer electrons in the respiratory chain acts as an antioxidant and helps protect cells against 
oxidative damage) since a probable mitochondrial disorder was considered.(Abe K, Matsuo 
Y, Kadekawa J, Inoue S 1999) The benefit of this compound is unclear but there are reports 
of potential positive effects in some patients, ameliorating clinical symptoms, upgrading 
enzyme function and slowing the course of disease, and as unpleasant side effects are rare, it 
is promptly introduced in these situations. 
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In addition, topical brimonidine (alfa2-receptors selective agonist, with minimal 
systemic adrenergic effects), may be used as a potencial neuroprotector as it lowers 
intraocular pressure.(Hernández, Urcola, and Vecino 2008)  
Initial efforts have been attempted in animal models in order to develop a gene-
replacement therapy, using an adeno-associated viral vector encoding Spg7 cDNA.  
There were several indicators of a positive effect of this therapeutic approach in mice 
with Spg7 gene inactivation, such as reduction in the number of swollen axons and in the 
percentage of axons containing abnormal mitochondria, and subsequent improvement of 
motor ability. However, mitochondrial morphology defects started to appear some time later, 
which suggests a transient effect of this therapeutic option .(Pirozzi et al. 2006) Gene therapy, 
isolated or in combination with cell replacement therapies, may represent a true hope in the 
control of such devastating condition.  
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